Hohimer Wealth Management LLC Buys 5,087 Shares of Hologic, Inc. (NASDAQ:HOLX) Posted by Patrick Bannon on Jul 31st, 2021 Share on Stocktwits
Hohimer Wealth Management LLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 41.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,501 shares of the medical equipment provider’s stock after acquiring an additional 5,087 shares during the quarter. Hohimer Wealth Management LLC’s holdings in Hologic were worth $1,168,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Grant Street Asset Management Inc. bought a new stake in Hologic in the 4th quarter valued at $25,000. Valeo Financial Advisors LLC increased its holdings in Hologic by 136.7% in the 1st quarter. Valeo Financial Advisors LLC now owns 355 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 205 shares during the period. GPS Wealth Strategies Group LLC bought a new stake in Hologic in the 1st quarter valued at $26,000. Atlas Private Wealth Advisors bought a new stake in Hologic in the 1st quarter valued at $30,000. Finally, Princeton Global Asset Management LLC bought a new stake in Hologic in the 1st quarter valued at $30,000. 92.69% of the stock is currently owned by institutional investors and hedge funds. Get Hologic alerts:
NASDAQ HOLX traded up $1.22 on Friday, hitting $75.04. 2,676,551 shares of the company were exchanged, compared to its average volume of 2,107,177. The firm’s 50 day simple moving average is $66.29. The company has a market cap of $19.02 billion, a P/E ratio of 9.62, a P/E/G ratio of 1.00 and a beta of 1.17. The company has a current ratio of 1.65, a quick ratio of 2.13 and a debt-to-equity ratio of 0.69. Hologic, Inc. has a 1-year low of $56.81 and a 1-year high of $85.00. Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 28th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.12 by $0.21. Hologic had a net margin of 35.98% and a return on equity of 67.74%. During the same quarter in the prior year, the business posted $0.75 EPS. On average, analysts expect that Hologic, Inc. will post 7.73 EPS for the current fiscal year.
In other Hologic news, insider Sean S. Daugherty sold 4,001 shares of the company’s stock in a transaction dated Monday, May 10th. The shares were sold at an average price of $65.02, for a total transaction of $260,145.02. Following the transaction, the insider now directly owns 26,613 shares in the company, valued at approximately $1,730,377.26. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website . 1.20% of the stock is owned by corporate insiders.
Several equities research analysts have issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Hologic in a report on Thursday. They issued a “buy” rating and a $95.00 price target on the stock. Evercore ISI upgraded shares of Hologic from an “in-line” rating to an “outperform” rating and set a $78.00 target price on the stock in a research note on Tuesday, July 6th. Morgan Stanley reduced their target price on shares of Hologic from $77.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday. Citigroup reduced their target price on shares of Hologic from $90.00 to $80.00 in a research note on Thursday, April 29th. Finally, SVB Leerink reduced their target price on shares of Hologic from $94.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, April 29th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Hologic has an average rating of “Buy” and a consensus target price of $85.38.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
Read More: Relative Strength Index
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX). Receive News & Ratings for Hologic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter .